Parathormone and bone-specific alkaline phosphatase for the follow-up of bone turnover in hemodialysis patients: Is it so simple?

Clinica Chimica Acta

Volumn 417, Issue , 2013, Pages 35-38

  Delanaye, Pierre ^a   Dubois, Bernard E ^a   Jouret, François ^a   Krzesinski, Jean Marie ^a   Moranne, Olivier ^b   Cavalier, Etienne ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

Author keywords

Bone turnover; Bone specific alkaline phosphatase; Parathormone

Indexed keywords

ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; PARATHYROID HORMONE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANALYTICAL PARAMETERS; ARTICLE; BONE TURNOVER; CHRONIC KIDNEY DISEASE; COMPARATIVE EFFECTIVENESS; CORRELATION ANALYSIS; CRITICAL DIFFERENCE; ENZYME ACTIVITY; ENZYME ANALYSIS; FEMALE; FOLLOW UP; HEMODIALYSIS; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL COMPUTING; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AGED; ALKALINE PHOSPHATASE; BONE AND BONES; BONE REMODELING; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; ORGAN SPECIFICITY; PARATHYROID HORMONE; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84872593384     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.12.009     Document Type: Article

References (21)

1. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009, S1-S130.
2. Urena P., Hruby M., Ferreira A., Ang K.S., de Vernejoul M.C. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 1996, 7:506-512.
3. Fletcher S., Jones R.G., Rayner H.C., et al. Assessment of renal osteodystrophy in dialysis patients: use of bone alkaline phosphatase, bone mineral density and parathyroid ultrasound in comparison with bone histology. Nephron 1997, 75:412-419.
4. Lehmann G., Ott U., Kaemmerer D., Schuetze J., Wolf G. Bone histomorphometry and biochemical markers of bone turnover in patients with chronic kidney disease stages 3-5. Clin Nephrol 2008, 70:296-305.
5. Couttenye M.M., D'Haese P.C., Van Hoof V.O., et al. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant 1996, 11:1065-1072.
6. Cavalier E., Delanaye P., Collette J., Krzesinski J.M., Chapelle J.P. Evaluation of different bone markers in hemodialyzed patients. Clin Chim Acta 2006, 371:107-111.
7. Reichel H., Esser A., Roth H.J., Schmidt-Gayk H. Influence of PTH assay methodology on differential diagnosis of renal bone disease. Nephrol Dial Transplant 2003, 18:759-768.
8. Jean G., Souberbielle J.C., Zaoui E., et al. Total and bone-specific alkaline phosphatases in haemodialysis patients with chronic liver disease. Clin Biochem 2012, 45:436-439.
9. Cavalier E., Delanaye P., Vranken L., et al. Interpretation of serum PTH concentrations with different kits in dialysis patients according to the KDIGO guidelines: importance of the reference (normal) values. Nephrol Dial Transplant 2012, 27:1950-1956.
10. Sardiwal S., Gardham C., Coleman A.E., Stevens P.E., Delaney M.P., Lamb E.J. Bone-specific alkaline phosphatase concentrations are less variable than those of parathyroid hormone in stable hemodialysis patients. Kidney Int 2012, 82:100-105.
11. Fraser C.G., Harris E.K. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 1989, 27:409-437.
12. Doumouchtsis K.K., Kostakis A.I., Doumouchtsis S.K., et al. Associations between osteoprotegerin and femoral neck BMD in hemodialysis patients. J Bone Miner Metab 2008, 26:66-72.
13. Nakashima A., Yorioka N., Doi S., Takasugi N., Shigemoto K., Kohno N. Osteoprotegerin and bone mineral density in hemodialysis patients. Osteoporos Int 2006, 17:841-846.
14. Tsuchida T., Ishimura E., Miki T., et al. The clinical significance of serum osteocalcin and N-terminal propeptide of type I collagen in predialysis patients with chronic renal failure. Osteoporos Int 2005, 16:172-179.
15. Urena P., Bernard-Poenaru O., Ostertag A., et al. Bone mineral density, biochemical markers and skeletal fractures in haemodialysis patients. Nephrol Dial Transplant 2003, 18:2325-2331.
16. Bervoets A.R., Spasovski G.B., Behets G.J., et al. Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. Am J Kidney Dis 2003, 41:997-1007.
17. Mundy G.R., Guise T.A. Hormonal control of calcium homeostasis. Clin Chem 1999, 45:1347-1352.
18. Christenson R.H. Biochemical markers of bone metabolism: an overview. Clin Biochem 1997, 30:573-593.
19. Garrett G, Sardiwal S, Lamb EJ, Goldsmith DJ. PTH-a particularly tricky hormone: why measure it at all in kidney patients? Clin J Am Soc Nephrol in press, http://dx.doi.org/10.2215/CJN.09580911.
20. Sanchez C., Lopez-Barea F., Sanchez-Cabezudo J., et al. Low vs standard calcium dialysate in peritoneal dialysis: differences in treatment, biochemistry and bone histomorphometry. A randomized multicentre study. Nephrol Dial Transplant 2004, 19:1587-1593.
21. Jean G., Chazot C., Charra B. 12months cinacalcet therapy in hemodialysis patients with secondary hyperparathyroidism: effect on bone markers. Clin Nephrol 2007, 68:63-64.